(NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that the government will be advancing several next-generation medical countermeasures (MCMs) formulated with its Thin Film Freezing technology into advanced preclinical testing.

（纳斯达克：TFFP）（“该公司”）是一家临床阶段的生物制药公司，专注于基于其专利薄膜冷冻（TFF）技术平台开发和商业化创新药物产品，今天宣布，政府将推进几项下一代医疗对策（MCMs），将其薄膜冷冻技术制成先进的临床前测试。

TFF Pharmaceuticals is collaborating with Leidos, a leading Fortune 500 information technology, engineering and science solutions and services leader, to develop next-generation MCMs designed to protect military and healthcare personnel against future chemical and biological (CB) threats. The research is funded by the Defense Advanced Research Projects Agency (DARPA) under a contract through the Personalized Protective Biosystems (PPB) program.

TFF Pharmaceuticals正在与领先的财富500强信息技术、工程和科学解决方案及服务领导者Leidos合作，开发下一代MCM，旨在保护军事和医疗保健人员免受未来化学和生物（CB）威胁。这项研究由国防高级研究计划局（DARPA）根据个性化保护生物系统（PPB）计划的合同资助。

Program Update The candidate MCMs delivered by Leidos to TFF Pharmaceuticals have been successfully formulated utilizing the Company’s proprietary Thin Film Freezing technology platform. Formulated materials have demonstrated neutralizing activity in well-validated in vitro models. The MCMs are now progressing into in vivo preclinical testing, which will be conducted at DARPA-contracted laboratories.

计划更新Leidos向TFF Pharmaceuticals提供的候选MCM已利用该公司专有的薄膜冷冻技术平台成功配制。配制的材料在经过充分验证的体外模型中显示出中和活性。MCM目前正在进行体内临床前测试，该测试将在DARPA签约实验室进行。

“Over the last several months, we have made significant progress working with Leidos to develop innovative new medical countermeasures utilizing our Thin Film Freezing technology,” said Dr. H.

“在过去的几个月里，我们与Leidos合作，利用我们的薄膜冷冻技术开发创新的新医疗对策，取得了重大进展，”H博士说。